Lantern Pharma Inc (LTRN)
6.30
+0.15
(+2.44%)
USD |
NASDAQ |
May 06, 10:00
Lantern Pharma Cash from Financing (Quarterly): -0.50M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.50M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | -2.182M |
| December 31, 2021 | -0.8728M |
| September 30, 2021 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2021 | -0.00 |
| March 31, 2021 | 64.29M |
| December 31, 2020 | -0.0003M |
| September 30, 2020 | -0.1028M |
| June 30, 2020 | 23.66M |
| March 31, 2020 | 0.1053M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 1.070M |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 1.85M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.182M
Minimum
Mar 2022
64.29M
Maximum
Mar 2021
4.498M
Average
--
Median
Jun 2019
Cash from Financing (Quarterly) Benchmarks
| Eyenovia Inc | 0.6143M |
| Cassava Sciences Inc | 1.143M |
| Alpine Immune Sciences Inc | 156.61M |
| Clearside Biomedical Inc | -0.257M |
| Poseida Therapeutics Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.385M |
| Cash from Investing (Quarterly) | 0.2562M |
| Free Cash Flow | -14.37M |
| Free Cash Flow Per Share (Quarterly) | -0.314 |
| Free Cash Flow Yield | -21.03% |